E Fund Management (Hong Kong) Co., Limited is expanding its range of thematic ETFs on the Hong Kong market with a product that, for the first time, combines Hong Kong and US biotech indices.
Sign up to our free newsletters
Article created by the editorial staff of ETFWorld.co.uk
Sharon Wang, CEO of E Fund HK
On March 23, 2026, the E Fund (HK) Solactive Biopharma Select Index ETF (code 3186), managed by E Fund Management (Hong Kong) Co., Limited, began trading on the Hong Kong Stock Exchange (HKEX).
The fund tracks the Solactive Biopharma Select Index, constructed through a methodology that selects up to 100 biotechnology and pharmaceutical companies listed in Hong Kong and the United States. The index assigns an aggregate weight of 65% to Hong Kong-listed securities and 35% to US-listed securities, with a maximum of 30 constituents from Hong Kong and at least 70 from the United States. Constituents are equally weighted within each region. The index is rebalanced semi-annually.
As of March 5, 2026, the composition reflected this structure: 65% exposure to the Hong Kong market and 35% to the US market. The index combines established US biopharmaceutical companies with Chinese biotech firms listed in Hong Kong, a segment that has gained prominence in recent years as a fundraising hub for companies from mainland China.
Sharon Wang, Chief Executive Officer of E Fund HK, commented: “We are very pleased with the successful launch of the E Fund (HK) Solactive Biopharma Select Index ETF. The Index is designed to reflect the performance of leading companies in the global biopharmaceutical field. It is currently the world’s only global biopharma index spanning both the Hong Kong and US stock markets. By bridging the world’s leading centers of R&D and its largest consumer market, the Index provides single-access exposure to 100 renowned, cutting-edge biopharmaceutical companies from China, the US, Europe, and other regions worldwide, making it a rare tool for capturing investment opportunities amid the globalization of the industry.”
Timo Pfeiffer, Chief Markets Officer at Solactive, commented: “We are pleased to continue our cooperation with E Fund with the launch of the E Fund Solactive Biopharma Select Index ETF. The biopharmaceutical sector remains an important area of innovation within global healthcare, and this index provides a rules-based and transparent representation of companies operating in this segment.”
The biotech and pharmaceutical sector continues to benefit from structural drivers: population aging, rising healthcare demand, and innovation in areas such as gene therapy and precision medicine. According to data released by E Fund HK, the underlying index recorded a cumulative performance of over 140% since March 20, 2020 (the base date), with a return of 75.7% during 2025. This data refers to the historical performance of the index and does not indicate the future results of the product.
The new ETF enters a context of growing interest in cross-market products in Hong Kong. In March 2026, other asset managers launched ETFs with a similar structure in technology sectors, including AI and technology companies, indicating a trend toward the expansion of vehicles that combine exposure to the United States and Hong Kong using methodologies with predefined regional weights.
Source : ETFWorld.co.uk
Subscribe to Our Newsletter
